Please assess the completion status of the following clinical trial:

Trial Title: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME)~* moderate and serious CFS/ME severity~* age 18-66 years~* informed consent~Exclusion Criteria:~* patients with fatigue, not fulfilling criteria for CFS~* pregnancy or lactation~* previous malignant disease, except basal cell carcinoma of skin and cervical carcinoma in situ~* previous long-term systemic treatment with immunosuppressive drugs such as cyclosporine, azathioprin, mycophenolate mofetil, except steroids e.g. in obstructive lunge disease.~* demyelinating disease, such as multiple sclerosis.~* heart failure.~* endogenous depression.~* lack of ability to comply to the protocol.~* multi-allergy with risk of serious drug reaction~* reduced renal function (creatinine \> 1.5 x UNL)~* reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* HIV positivity. Evidence of clinically significant infection. Previous viral hepatitis with risk of reactivation. High risk of opportunistic infections. Latent tuberculosis must be treated before inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).